PedAM
Pediatric Disease Annotations & Medicines
| Disease | panuveitis |
| Phenotype | C0003873|rheumatoid arthritis |
| Sentences | 2 |
| PubMedID- 23341733 | Recently, infliximab has been used as a novel immunomodulatory agent, particularly in uveitis refractory to treatment, panuveitis associated with behcet’s disease, rheumatoid arthritis, and crohn’s disease.28 infliximab was shown to inhibit the functional activity of tnf-α in several in vitro studies.29,30 it has been suggested that infliximab exerts its clinical effects in patients with uveitis through various mechanisms, which include reducing serum levels of inflammatory mediators by blocking tnf-α, preventing lymphocyte migration, and decreasing levels of vascular endothelial growth factor.31 binding of infliximab to soluble tnf-α brings about a decrease in bioactivity, while its binding to membrane-bound tnf-α results in cytotoxicity through complement-dependent or antibody-dependent cell-mediated mechanisms. |
| PubMedID- 24851041 | Recently, infliximab has been used as a novel immunomodulatory agent, particularly in uveitis refractory to treatment, panuveitis associated with behçet’s disease, rheumatoid arthritis, and crohn’s disease.55 infliximab was shown to inhibit the functional activity of tnf-α in several in vitro studies.56,57 it has been suggested that infliximab exerts its clinical effects in patients with uveitis through various mechanisms, which include reducing serum levels of inflammatory mediators by blocking tnf-α, preventing lymphocyte migration, and decreasing levels of vascular endothelial growth factor.58 binding of infliximab to soluble tnf-α brings about a decrease in bioactivity, while its binding to membrane-bound tnf-α results in cytotoxicity through complement-dependent or antibody-dependent cell-mediated mechanisms. |
Page: 1